Compare IPW & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPW | RLYB |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 44.6M |
| IPO Year | 2021 | 2021 |
| Metric | IPW | RLYB |
|---|---|---|
| Price | $1.24 | $8.09 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 184.4K | 96.8K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $66,142,779.00 | $858,000.00 |
| Revenue This Year | $149.67 | N/A |
| Revenue Next Year | $15.04 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.00 |
| 52 Week Low | $0.43 | $0.23 |
| 52 Week High | $29.10 | $11.49 |
| Indicator | IPW | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 28.39 | 49.20 |
| Support Level | $0.50 | $7.90 |
| Resistance Level | $2.79 | $11.49 |
| Average True Range (ATR) | 0.16 | 0.57 |
| MACD | 0.06 | -0.31 |
| Stochastic Oscillator | 3.94 | 10.82 |
iPower Inc is a United States-based online retailer and supplier of consumer home, pet, garden, outdoor, and consumer electronics products. It also operates as a provider of value-added ecommerce services for third-party products and brands. The company's capabilities include a spectrum of online channels, fulfillment capacity, a network of warehouses serving the U.S., last-mile delivery partners, and a differentiated business intelligence platform. The company's sales channels currently include Amazon Vendor, Amazon 3P, Walmart.com, TikTok, Temu, and other marketplaces, as well as its own e-commerce websites, such as simpledeluxe.com and more. Additionally, it is developing in-house branded products and through supply chain partners, which include iPower, Simple Deluxe, and other brands.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.